News

Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update

AUSTIN, Texas, May 23, 2017 (GLOBE NEWSWIRE) — Aeglea BioTherapeutics, Inc., (AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today provided an AEB1102 program and corporate update. AEB1102, the company’s lead investigational molecule, is an engineered human enzyme designed to degrade the amino acid arginine and is being developed to treat two extremes of arginine metabolism.

2017-06-27T11:55:51+00:00